News

At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in Diabetic macular edema.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.

Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida

Promising innovations are not one-size-fits-all

Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.

The Early Detection of Vision Impairment in Children (EDVI) Act would establish the first federal program to address children’s vision and eye health.

At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.

GLOW2 follows the GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS and 89% decreased risk of developing sight-threatening complications.

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March.

Organization eyes green practices, shifting ophthalmology landscape.

This year at ARVO, Anand Swaroop, PhD, was awarded the Friedenwald Award Lecture 2024. He spoke with the Eye Care Network about this lecture and what the award meant to him.

This year at ARVO, Emily Chew, MD, was awarded the Proctor Award Lecture. She spoke with the Eye Care Network about this lecture and what the award meant to her.

The trial is a study of twice daily tanfanercept ophthalmic solution 0.25% and 1.0% and will leverage key insights from the concluded Phase III VELOS-3 study.

This year at ARVO, Daniel Saban PhD, was awarded the Cogan Award Lecture. He spoke with the Eye Care Network about this lecture and what the award meant to him.

Alcon agreed to acquire Belkin Vision and the Belkin Vision Eagle and plans to provide additional details when the deal is closed.

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

Physicians should consider the roles of verbal and ocular anesthesia.

David Eichenbaum, MD, spoke with Modern Retina about the phase 3 trial of sozinibercept at the 2024 Retina World Congress meeting.

Modern Retina spoke with Paulo-Eduardo Stanga, MD, from The Retina Clinic London, London, United Kingdom at the 2024 Retina World Congress meeting.

Red light has been receiving increased attention as a potential candidate to combat myopia. The daily use of 650-nm low-level red light for 1 year slowed the progression of spherical equivalent error and axial length without safety concerns.

Christine Kay, MD, spoke with Modern Retina to share insights from her presentation on longitudinal BCVA and safety analysis of mutation-agnostic MCO-010 optogenetic therapy For retinitis pigmentosa

David Almeida, MD, PhD, MBA, presented on gene therapy associated uveitis at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.

Noha A. Sherif, MD, and Sandra Hoyek, MD, conducted a retrospective chart review to identify the clinical characteristics of the injured eyes that may be associated with visual recovery in this patient population.